La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Personalis a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Personalis..

Personalis (NASDAQ:PSNL) Azioni, Catena delle Opzioni

Personalis

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Personalis Inc

Biotech

News

General

ANIX

Anixa Biosciences Sets November 8 For Public Release Of Phase 1 Breast Cancer Vaccine Data At SITC Annual Meeting

TD Cowen analyst Nick Yako maintains Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) with a Hold and raises the price target from $130 to $150.

Price Target

Analyst Ratings

QLYS

TD Cowen Maintains Hold on Qualys, Raises Price Target to $150

Management

FTHM

Fathom Holdings Announced It Has Promoted Joanne Zach To CFO

<ul>
<li>$800 Million AAA-Rated Personal Loan and $200 Million AA-Rated Auto Loan Asset Backed Securitizations, with $5.5 Billion raised across all ABS transactions year-to-date</li>
<li>Pagaya remains the #1 personal loan ABS issuer in the U.S.</li>
</ul>
Pagaya Technologies LTD. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) ("Pagaya" or "the Company"), a global technology company delivering AI-driven product solutions for the financial ecosystem, today announced the closing of PAID 2024-10 and RPM 2024-3, totaling $1 billion in size across both deals. This represents the Company's fourth AAA-rated personal loan ABS transaction and its first AA-rated auto ABS transaction.
A total of 28 unique investors participated across these two transactions, the majority of which were repeat investors. The deal was substantially oversubscribed, reflecting continued strong investor demand for Pagaya's robust, AI-enabled consumer credit assets.
Pagaya continues to meet the needs of prominent financial institutions and deliver efficient, fit-for-market structures across the financial ecosystem. Qualified institutional buyers purchased notes backed by personal and auto loans that will be originated by Pagaya's lending partners on Pagaya's AI-powered network.

Pagaya Raises $1B Across Two New Personal Loan And Auto ABS Deals, Signaling Strong Capital Markets Demand; A Total Of 28 Investors Participated Across These Two Transactions, The Majority Of Which Were Repeat Investors

WIIM

Cummins shares are trading higher after Baird raised its price target on the stock from $330 to $372.

Earnings

Earnings Misses

MFA Finl Q3 2024 Distributable EPS $0.37, NII $50.625M

GlobalFoundries shares are trading higher. Baird maintained an Outperform rating on the stock.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/580f253b846faa000139ba71/robert-moskow">TD Cowen analyst Robert Moskow</a> upgraded the rating for The Clorox Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) from Sell to Hold and raises the price target from $155 to $170. Clorox shares closed at $162.42 on Tuesday. <a href="https://www.benzinga.com/quote/CLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Trevor Young upgraded Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) from Underweight to Equal-Weight and raised the price target from $17 to $25. Revolve shares closed at $26.02 on Tuesday. <a href="https://www.benzinga.com/quote/RVLV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/616e99feb650db000151570b/rick-bienkowski">Leerink Partners analyst Rick Bienkowski</a> upgraded the rating for Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) from Market Perform to Outperform and increased the price target from $27 to $39. Beam Therapeutics shares closed at $23.93 on Tuesday. <a href="https://www.benzinga.com/quote/BEAM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst David Begleiter upgraded Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Hold to Buy and lowered the price target from $135 to $110. Celanese shares closed at $91.00 on Tuesday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>

Considering buying CLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="547" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png" alt="" class="wp-image-632747" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-1024x547.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49-768x410.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06082758/image-49.png 1230w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

BEAM

RVLV

This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday

TSLA

Tesla shares are trading higher following Donald Trump's successful presidential election campaign.

Guidance

CVS Executive Says Company Is Not Providing A Formal Outlook For 2024 At This Stage

Chubb shares are trading higher. Wells Fargo raised its price target on the stock from $106 to $108.

Health Care

STXS

Stereotaxis Announces University Of Kansas Medical Center Physicians Have Treated The First Patients Using The Company's Genesis Robotic Magnetic Navigation System

Aflac shares are trading higher. Wells Fargo raised its price target on the stock from $106 to $107.

TD Cowen analyst Oliver Chen downgrades Grocery Outlet Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) from Buy to Hold and lowers the price target from $25 to $16.

Downgrades

TD Cowen Downgrades Grocery Outlet Holding to Hold, Lowers Price Target to $16

Contracts

YYGH

YY Group Holding's Hong Ye Group Announces SGD$4.7M In Contracts

TD Cowen analyst Vivien Azer downgrades Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) from Buy to Hold and lowers the price target from $50 to $48.

BF/B

TD Cowen Downgrades Brown-Forman to Hold, Lowers Price Target to $48

CHTR

Charter Communications shares are trading higher after Benchmark maintained a Buy rating on the stock and raised its price target from $440 to $450.

CLBT

Cellebrite CEO Yossi Carmil To Step Down After Nearly 20 Years; Executive Chairman Thomas E. Hogan To Serve As Interim CEO Pending New Appointment

Piper Sandler analyst Christopher Raymond maintains Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Overweight and raises the price target from $4 to $5.

KPTI

Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Raises Price Target to $5

American Electric Power Company, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) reported the&nbsp;third quarter revenue of&nbsp;$5.42 billion,&nbsp;missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769709/aep-reports-third-quarter-2024-earnings-introduces-new-growth-rate-and-capital-plan" rel="noreferrer noopener">consensus of&nbsp;$5.434 billion</a>.
Commercial load increased more than&nbsp;10%&nbsp;year-over-year through the&nbsp;third quarter. The company projects commercial load to grow an average of 20% annually over the next three years on the basis of customer contracts signed so far.
Total energy distribution fell 1.0% in the Vertically Integrated Utilities segment and&nbsp;rose 4.1% in the Transmission &amp; Distribution Utilities segment.&nbsp;
Adjusted operating earnings rose to&nbsp;$985.4 million from&nbsp;$923.8 million a year ago.&nbsp;
Adjusted operating earnings from Vertically Integrated Utilities rose to&nbsp;$572.4 million from&nbsp;$520.0 million the prior year, and AEP Transmission Holdco grew to&nbsp;$214.7 million from&nbsp;$202.9 million&nbsp;in the prior&nbsp;year&#8217;s quarter.
Adjusted EPS&nbsp;of&nbsp;$1.85 <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beat the consensus of&nbsp;$1.80</a>.
FY24&nbsp;Outlook: American Electric Power narrowed adjusted operating earnings per share&nbsp;guidance&nbsp;from&nbsp;$5.53 &#8211; $5.73&nbsp;to $5.58 &#8211; $5.68<a target="_blank" href="https://www.benzinga.com//node/40038448" rel="noreferrer noopener"> vs.&nbsp;consensus of&nbsp;$5.62</a>.
The company sees FY25 adjusted EPS of $5.75 &#8211; $5.95 <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">vs consensus of $5.98</a>. The company now expects a long-term growth rate outlook of 6% to 8% (vs. 6% to 7% prior).
Bill Fehrman, AEP president and chief executive officer, said, &#8220;AEP has a strong foundation and significant growth opportunities ahead, and we are confident in our ability to execute our strategy and deliver on our promises. This confidence is reflected in our new&nbsp;6%-8%&nbsp;long-term growth rate and expanded capital investment plan of&nbsp;$54 billion&nbsp;over the next five years, along with our commitment to a strong balance sheet.&#8221;
Investors can gain exposure to the stock via&nbsp;Listed Funds Trust TrueShares Eagle Global Renewable Energy Income ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNWZ#NYSE">RNWZ</a>)&nbsp;SPDR Select Sector Fund – Utilities&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>).
Price Action: AEP shares are down 0.90% at $99.50 premarket at the last check Wednesday.
Photo by american-public-power-association- for Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41254312/hurricane-milton-descends-on-florida-analysts-warn-of-impact-on-disney-nexteras-flo" target="_blank" rel="noreferrer noopener">Hurricane Milton Descends On Florida: Analysts Warn Of Impact On Disney, NextEra&#8217;s Florida Power &amp; Light, Regional Banks</a></li>
</ul>

Equities

Large Cap

RNWZ

American Electric Power Q3: EPS Beat, Revenue Miss, 10% Commercial Load Jump & More

Lake Street analyst Thomas Flaten maintained a Buy rating on Personalis (PSNL – Research Report) today and set a price target of $8.00. The company...

Lake Street Remains a Buy on Personalis (PSNL)

In a report released yesterday, Mark Massaro from BTIG maintained a Buy rating on Personalis (PSNL – Research Report), with a price target of $7.00...

Personalis (PSNL) Receives a Buy from BTIG

Personalis file to sell 3.5M shares of common stock for holders

Small-cap stocks have climbed recently. Here are the ones most poised for further upside

Small-caps get a lift after Fed's jumbo rate cut; see top 20 names per SA Quant ratings

Small-caps get a lift after Fed's jumbo rate cut; see top 20 names in SA Quant ratings

Small-caps get a lift after Fed's jumbo rate cut: See top 20 names in SA Quant ratings

Lake Street Keeps Their Buy Rating on Personalis (PSNL)

Hedge funds pile into healthcare stocks amid dip, Goldman Sachs says

The Proper Play On Personalis

AMSC

AQST

AVDV

AVUV

AXGN

BFLY

BYRN

CALF

CDNA

CLOV

COMM

CRMD

CURI

DAVE

DFAS

DFSV

ESOA

EVER

FNDA

GASS

GTHX

HMENF

HRTG

HYLN

IGIC

INSG

JAGGF

MESO

OPFI

PRAX

PSIX

PSNL

RMTI

SCHA

SLNCF

SUPV

USAP

VIRC

Press Releases

Personalis to Announce Second Quarter 2024 Financial Results

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

Personalis Reports Second Quarter 2024 Financial Results

Personalis and Tempus Announce Expanded Collaboration

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Personalis to Participate at Upcoming Investor Conferences

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Comments

Personalis

Personalis (PSNL) Opzioni

Personalis (NASDAQ:PSNL) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO